Hims & Hers Health (HIMS) Q2 2026 earnings summary

Executive summary

• Revenue grew 38–40% year-over-year in Q2 2026 to $753–$753.2 million, driven by subscriber growth, international expansion (notably the Eucalyptus acquisition), and AI-powered care.

• Net loss was $86–$86.3 million for Q2 2026, primarily due to higher operating expenses, legal contingencies, and restructuring charges.

• Subscriber base increased 19% year-over-year to nearly 2.9–3 million, with monthly revenue per average subscriber up 21% to $92.

• Strategic acquisitions in North America, Europe, Australia, and Japan accelerated global reach and diversified offerings.

• AI and technology investments are enhancing personalized care, operational efficiency, and global scale.

Financial highlights

• Q2 2026 revenue: $753–$753.2 million, up 38–40% year-over-year; U.S. revenue: $621.8–$622 million, up 16%.

• International revenue increased over 17-fold year-over-year to $131–$131.4 million, with Eucalyptus contributing significantly.

• Adjusted EBITDA: $60–$60.3 million (8% margin), down from $82.2 million (15%) in Q2 2025; GAAP net loss: $86–$86.3 million.

• Gross margin: 64%, down from 76% year-over-year, due to product mix and international expansion.

• Cash and investments totaled $840–$841 million at quarter end.

Outlook and guidance

• Q3 2026 revenue guidance: $880–$900 million; Adjusted EBITDA: $75–$95 million (margin 9–11%).

• Full-year 2026 revenue outlook raised to $3.1–$3.3 billion (32–41% growth); Adjusted EBITDA: $275–$325 million.

• Long-term ambition: at least $6.5 billion revenue and $1.3 billion Adjusted EBITDA by 2030.

• International business expected to generate at least $600 million in 2026, operating at or near breakeven.

• Liquidity is considered sufficient for at least the next 12 months.